A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

NCT01704963 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Mature B-cell Neoplasms

Interventions

DRUG: PCI-32765

Sponsor

Janssen Pharmaceutical K.K.

Collaborators

[object Object]